Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 20, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that President and CEO Murray Kessler will present at the 37th Annual J.P. Morgan Global Healthcare Conference at 5:00 PM EST on Tuesday,...
-
Dec 10, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is indicated for the...
-
Nov 28, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate, 0.05%) Spray brought by Promius Pharma...
-
Nov 27, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its AB rated abbreviated new drug application referencing Solaraze® Gel, 3% (diclofenac sodium gel, 3%). Solaraze® Gel, 3%...
-
Nov 26, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the first to file generic version of Ultravate® Lotion...
-
Nov 8, 2018
Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion, reported net loss of $68 million compared to a net income of $45 million last year and reported diluted loss per share of $0.49
-
Oct 31, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on December 18, 2018 to shareholders of record on...
-
Oct 29, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Anacor Pharmaceuticals, Inc., initiated patent litigation on October 25, 2018 in the United States District Court for the District of...
-
Oct 26, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Ltd. and Opiant Pharmaceuticals initiated patent litigation on October...
-
Oct 25, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter calendar year 2018 financial results on Thursday, November 8, 2018. The Company will host a conference...
-
Oct 15, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Androgel® Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g...
-
Oct 8, 2018
Murray S. Kessler, former Chief Executive Officer and President at the Lorillard Tobacco Company, appointed President, CEO and member of the Board of Directors effective immediately Proven track...
-
Oct 1, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken...
-
Sep 28, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Picato® (ingenol mebutate) gel, 0.015%, 0.05% brought by LEO Pharma Inc., LEO...
-
Sep 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of...
-
Aug 29, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously...
-
Aug 9, 2018- Expands Consumer Healthcare Americas growth strategy with innovative offering for an Rx to OTC brand switch and store brand solution
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the...
-
Aug 9, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals (Rx) business following the Company's...
-
Aug 9, 2018
Realized second quarter 2018 GAAP ("reported") net sales of $1.2 billion, reported net income of $36 million compared to a net loss of $70 million last year and reported diluted earnings per share...
-
Aug 1, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on September 18, 2018 to shareholders of record on...
-
Jul 26, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter calendar year 2018 financial results on Thursday, August 9, 2018. The Company will host a conference...
-
May 30, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the Jefferies 2018 Healthcare Conference at 8:30 AM EST on Tuesday,...
-
May 24, 2018
Perrigo Company plc (NYSE; TASE: PRGO) announced today that Promius Pharma LLC initiated patent litigation on May 22, 2018 in the U.S. District Court for the Eastern District of Texas, regarding...
-
May 14, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Sun Pharmaceutical Industries, Inc. and MiCal Pharmaceuticals LLC initiated patent litigations on May 9 and 10, 2018, in the U.S....
-
May 11, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it expects to receive a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its Abbreviated New Drug...
-
May 8, 2018
Realized first quarter 2018 GAAP ("reported") net sales of $1.2 billion, reported net income of $81 million compared to $72 million last year, an increase of 12.9%, and reported diluted earnings...
-
May 3, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on June 19, 2018 to shareholders of record on June 1, 2018.
-
Apr 24, 2018- Separately, the Company announced that it will present at the Deutsche Bank Healthcare Conference on May 9, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its first quarter calendar year 2018 financial results on Tuesday, May 8, 2018. The Company will host a conference call...
-
Apr 11, 2018- Consumer friendly dosing provides patients with needed heartburn alternative
Perrigo Company plc (NYSE; TASE: PRGO) and its partner Dexcel Pharma Technologies, Ltd., today announced the launch of store brand Omeprazole Delayed Release Orally Disintegrating Tablets 20mg...
-
Mar 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex® DM Maximum...
-
Mar 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the 2018 Barclays Global Healthcare Conference at 1:35 PM EST on...
-
Mar 1, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission and...
-
Mar 1, 2018
Fourth Quarter Realized fourth quarter 2017 GAAP ("reported") net sales of $1.3 billion, reported net income of $73 million and reported diluted earnings per share ("EPS") of $0.52 compared to a...
-
Feb 27, 2018Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018
Select Preliminary Unaudited Calendar Year 2017 Results Delivered strong calendar year 2017 GAAP ("reported") and adjusted net sales at the high end of previous guidance range and operating cash...
-
Feb 20, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of...
-
Feb 20, 2018
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ronald L. Winowiecki has been appointed Chief Financial Officer....
-
Feb 15, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on March 20, 2018 to shareholders of record on March 2,...
-
Feb 8, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2017 financial results on Tuesday, February 27, 2018. The Company will also host a...
-
Jan 30, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Soolantra® (ivermectin) cream, 1%....
-
Jan 26, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton® Gel (clindamycin phosphate...
-
Jan 24, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for the generic version of Estrace® Cream (estradiol vaginal...
-
Jan 24, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo® (adapalene...
-
Jan 8, 2018- Uwe Röhrhoff, former Chief Executive Officer at Gerresheimer AG, appointed President, CEO and board member effective January 15, 2018
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of Uwe Röhrhoff as Chief Executive Officer,...
-
Jan 3, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Prolensa® (bromfenac ophthalmic...
-
Jan 2, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference at 12:00 PM EST...